Michael Schwarz, MD
Cardiology · Rutherford, NJNPI 1952349763
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $34,300 of the $40,103 with a category attached, or 85.5%. Roche Health Solutions Inc. accounts for 85.5% of it on its own, with 44 other manufacturers making up the rest. Reporting peaked in 2019 at $23,852 and has fallen 99.5% since, to $122 in 2025. Among cardiology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 260 payments — averaging $154.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Roche Health Solutions Inc.$34K
- Philips North America LLC$2K
- Amgen$472
- Novo Nordisk$406
- Bayer$318
- Kowa Pharmaceuticals America, Inc.$236
- plus $2K from 39 others
Across 14 payments — averaging $125.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amryt Pharma Holdings Ltd$2K
- Chiesi USA, Inc.$50
What the payments were for
- Consulting fees$2,0005%
- Speaking & faculty fees$34,30086%
- Food & beverage$3,7509%
- Education$530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$40,103 in reported general payments places this provider in the 95th percentile of 31 cardiology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 50 | $65,313 |
| EliquisApixaban | 49 | $63,916 |
| Repatha SureclickEvolocumab | 72 | $58,980 |
| OzempicSemaglutide | 22 | $30,250 |
| JardianceEmpagliflozin | 33 | $29,845 |
| Praluent PenAlirocumab | 14 | $17,653 |
| EntrestoSacubitril/Valsartan | 16 | $15,226 |
| BrilintaTicagrelor | 13 | $11,610 |
| Liothyronine Sodium | 178 | $10,637 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $5,163 |
| Pitavastatin Calcium | 11 | $3,956 |
| Potassium Chloride | 34 | $2,007 |
| Levothyroxine Sodium | 116 | $1,426 |
| Omega-3 Acid Ethyl Esters | 18 | $1,245 |
| SotalolSotalol Hcl | 70 | $1,180 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $172 | $65,31350 claims |
| PfizerEliquis | $147 | $63,91649 claims |
| Novo NordiskOzempic | $406 | $30,25022 claims |
| Boehringer IngelheimJardiance | $38 | $29,84533 claims |
| NovartisEntresto | $45 | $15,22616 claims |
| AstraZenecaBrilinta | $136 | $11,61013 claims |
| GSKBreo Ellipta | $90 | $5,16313 claims |
| AbbVieSynthroid, Armour Thyroid | $41 | $2,00326 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 31 cardiology providers in New Jersey.
Other cardiology in Rutherford
- Beverly DemchukOcean$12K
- Lei XuBrown Hills$10K
- Sarika SharmaRochelle Park$9K
- Vasant Paul KateBrick$7K
- Pragnesh GadhviUnion City$7K
- Ebrahim IssaTeaneck$5K
- Ricardo CalvoEdison$5K
- Marc ColmerNeptune$5K
- Ian MolkEdison$4K
- Tanveer AhmadBrick$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.